BSX FY 2024 Earnings Report — Boston Scientific Corporation Revenue & Financial Results | Market Cap Arena

Boston Scientific CorporationBSX

FY 2024 Earnings

Reported February 18, 2025

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2024	Prior Q	FY 2023	QoQ Change	YoY Change
Revenue	$16.7B	—	$14.2B	—	17.6%
Op. Income	$2.6B	—	$2.2B	—	20.8%
Gross Margin	61.3%	—	62.0%	—	-0.7pp
Net Margin	11.1%	—	11.2%	—	-0.1pp
EPS (Diluted)	$1.25	—	$1.07	—	16.5%
Free Cash Flow	$2.6B	—	$1.7B	—	55.3%

Revenue Flow

Item	Amount
REVENUE	$16.7B
Cost of Revenue	$6.5B
GROSS PROFIT	$10.3B
R&D Expenses	$1.6B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$6.0B
Other Expenses	$33M
Operating Expenses	$7.6B
Cost & Expenses	$14.1B
OPERATING INCOME	$2.6B
Interest Income	$107M
Interest Expense	$387M
Other Income/Expenses	-$353M
INCOME BEFORE TAX	$2.3B
Income Tax Expense	$436M
Net Income from Continuing Ops	$1.8B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.9B
Net Income Deductions	$1M
BOTTOM LINE NET INCOME	$1.9B
D&A	$1.3B
EBIT	$2.7B
EBITDA	$3.9B
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$16.7B
Cost of Revenue	$6.5B
GROSS PROFIT	$10.3B
R&D Expenses	$1.6B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$6.0B
Other Expenses	$33M
Operating Expenses	$7.6B
Cost & Expenses	$14.1B
OPERATING INCOME	$2.6B
Interest Income	$107M
Interest Expense	$387M
Other Income/Expenses	-$353M
INCOME BEFORE TAX	$2.3B
Income Tax Expense	$436M
Net Income from Continuing Ops	$1.8B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.9B
Net Income Deductions	$1M
BOTTOM LINE NET INCOME	$1.9B
D&A	$1.3B
EBIT	$2.7B
EBITDA	$3.9B
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$1.8B
Depreciation & Amortization	$1.3B
Stock-Based Compensation	$266M
Deferred Income Tax	$0
Other Non-Cash Items	$516M
Change in Working Capital	-$462M
OPERATING CASH FLOW	$3.4B
Capital Expenditure	-$790M
Acquisitions (Net)	-$4.6B
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	-$257M
NET CASH FROM INVESTING	-$5.7B
Net Debt Issuance	$1.8B
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	-$243M
NET CASH FROM FINANCING	$1.8B
FREE CASH FLOW	$2.6B
Net Change in Cash	-$449M

Balance Sheet

Item	Amount
Cash & Equivalents	$414M
Short-Term Investments	$0
Net Receivables	$2.6B
Inventory	$2.8B
Other Current Assets	$831M
TOTAL CURRENT ASSETS	$6.9B
PP&E (Net)	$3.7B
Goodwill	$17.1B
Intangible Assets	$6.7B
Long-Term Investments	$555M
Tax Assets	$3.7B
Other Non-Current Assets	$749M
TOTAL NON-CURRENT ASSETS	$32.5B
TOTAL ASSETS	$39.4B
Account Payables	$960M
Short-Term Debt	$1.8B
Deferred Revenue	$306M
Other Current Liabilities	$491M
TOTAL CURRENT LIABILITIES	$6.4B
Long-Term Debt	$8.8B
Deferred Revenue NC	$329M
Deferred Tax Liabilities	$155M
Other Non-Current Liabilities	$1.1B
TOTAL NON-CURRENT LIABILITIES	$11.0B
TOTAL LIABILITIES	$17.4B
Common Stock	$17M
Additional Paid-In Capital	$21.1B
Retained Earnings	$2.7B
Treasury Stock	-$2.3B
Accum. Other Comp. Income	$275M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$21.8B
Minority Interest	$233M
TOTAL EQUITY	$22.0B
TOTAL LIABILITIES & EQUITY	$39.4B
Total Debt	$11.1B
Net Debt	$10.7B